Antiparkinson's Disease Drugs

Correct Answer

D — Typical antipsychotic

Rationale

Haloperidol is classified as a typical antipsychotic — the older generation of antipsychotic drugs characterized by high dopamine D2 receptor blockade throughout the brain. This high D2 affinity makes haloperidol absolutely contraindicated in Parkinson's disease psychosis: blocking the D2 receptors in the nigrostriatal pathway that are already functionally depleted causes severe motor deterioration. Atypical antipsychotics such as clozapine and quetiapine have lower D2 affinity and are used instead when psychosis requires treatment in Parkinson's disease. Cholinesterase inhibitors increase acetylcholine availability and are used for cognitive impairment. Dopamine agonists stimulate dopamine receptors to treat motor symptoms.

Correct Answer

B — Risperidone

Rationale

Risperidone is classified as an atypical antipsychotic with high dopamine D2 receptor affinity. Despite belonging to the atypical category, its D2 affinity is high enough to cause significant nigrostriatal blockade, making it contraindicated in Parkinson's disease psychosis for the same reason as typical antipsychotics such as haloperidol. Clozapine and quetiapine are atypical antipsychotics with low D2 affinity that can be used safely in Parkinson's disease psychosis without worsening motor symptoms. Pimavanserin is a selective serotonin 5-HT2A inverse agonist with no dopamine receptor activity — it is the only drug approved specifically for Parkinson's disease psychosis and carries no risk of motor worsening.

Correct Answer

A — Cholinesterase inhibitor used off-label for Parkinson's disease dementia

Rationale

Donepezil is classified as a cholinesterase inhibitor used off-label for Parkinson's disease dementia. It inhibits acetylcholinesterase, increasing acetylcholine availability in cortical synapses to partially compensate for the cholinergic deficits that contribute to cognitive impairment in Parkinson's disease. However, it lacks the specific Food and Drug Administration approval for this indication that rivastigmine carries. Rivastigmine is the only cholinesterase inhibitor with formal approval specifically for Parkinson's disease dementia, making it the drug to name when Step 1 questions ask about this indication specifically. Donepezil is acceptable in clinical practice but is used off-label. It is not a dopamine agonist or an antipsychotic.

Correct Answer

C — Benzodiazepine

Rationale

Clonazepam is classified as a benzodiazepine — a drug class that enhances the effect of gamma-aminobutyric acid at the gamma-aminobutyric acid A receptor, producing sedation and suppression of abnormal motor activity during sleep. In the context of Parkinson's disease, clonazepam is used for the symptomatic management of rapid eye movement sleep behavior disorder — a condition in which patients act out dream content because the normal motor paralysis of rapid eye movement sleep is lost. This sleep disorder is highly associated with synucleinopathies including Parkinson's disease and may precede motor symptoms by years. Clonazepam is not a dopamine agonist, an anticholinergic agent, or a monoamine oxidase B inhibitor.

Correct Answer

B — Bladder-targeted antimuscarinic agent

Rationale

Oxybutynin is classified as a bladder-targeted antimuscarinic agent — a drug that blocks muscarinic receptors in the detrusor muscle of the bladder to reduce urinary urgency, frequency, and nocturia associated with detrusor overactivity. In Parkinson's disease, urinary symptoms are a common autonomic complication. Oxybutynin can provide symptomatic benefit but carries cognitive risk in older patients because muscarinic blockade in the brain impairs memory and can cause confusion — a concern in patients who already have Parkinson's disease-related cognitive vulnerability. Alpha-1 adrenergic agonists such as midodrine raise blood pressure by vasoconstriction. Mineralocorticoids such as fludrocortisone expand plasma volume. Dopamine agonists treat motor symptoms.

Correct Answer

D — Cholinesterase inhibitor with limited supporting evidence specifically in Parkinson's disease dementia

Rationale

Galantamine is classified as a cholinesterase inhibitor, sharing its mechanism class with rivastigmine and donepezil. However, it has less supporting evidence specifically in Parkinson's disease dementia than either of the other two agents. Rivastigmine holds the only Food and Drug Administration approval specifically for Parkinson's disease dementia and is the drug most testable at the Step 1 level for this indication. Donepezil is used off-label with a reasonable evidence base. Galantamine is occasionally used but is the weakest of the three options in Parkinson's disease-specific evidence. Galantamine is not a dopamine agonist and carries no cognitive-protective dopaminergic mechanism. Anticholinergic agents are avoided in patients with Parkinson's disease dementia because muscarinic blockade worsens cognitive function — the opposite of what a cholinesterase inhibitor achieves.

Correct Answer

B — Amantadine

Rationale

The skin finding described — a mottled, net-like purplish discoloration called livedo reticularis — is the most distinctive adverse effect of amantadine and a classic Step 1 identification point. It is caused by amantadine-induced changes in cutaneous blood flow and appears in a substantial proportion of patients on long-term therapy. It is benign and reverses when amantadine is discontinued. Livedo reticularis is specific to amantadine and is not associated with any other antiparkinson drug class — not levodopa, dopamine agonists, monoamine oxidase B inhibitors, or catechol-O-methyltransferase inhibitors. It is often accompanied by peripheral edema through the same vascular mechanism. Entacapone is associated with orange urine discoloration. Rasagiline and pramipexole do not cause skin discoloration.

Correct Answer

D — Amantadine is excreted unchanged by the kidneys, so reduced renal function decreases clearance and causes drug accumulation

Rationale

Amantadine is eliminated primarily by renal excretion as unchanged drug — it undergoes minimal hepatic metabolism. When kidney function is reduced, the clearance of amantadine falls in proportion to the reduction in glomerular filtration rate, causing the drug to accumulate in the body at doses that would be safe in a patient with normal renal function. Accumulated amantadine increases the risk of neuropsychiatric toxicity — confusion, hallucinations, and agitation — which are already more prominent in elderly patients and those with cognitive impairment. Dose reduction or extended dosing intervals are required to maintain safe plasma concentrations. Amantadine is not converted to nephrotoxic metabolites, does not undergo significant hepatic metabolism, and its protein binding is not substantially affected by renal disease. This renal excretion pattern is shared with pramipexole among antiparkinson drugs.

Correct Answer

A — Acute treatment of drug-induced dystonia via intramuscular or intravenous injection

Rationale

Benztropine is available in an injectable formulation — both intramuscular and intravenous — which allows it to be used for acute drug-induced dystonia. Drug-induced dystonia is an acute movement disorder characterized by sustained involuntary muscle contractions causing abnormal postures, most commonly triggered by antipsychotics or antiemetics that block dopamine D2 receptors. In the striatum, this D2 blockade disrupts the dopamine-acetylcholine balance and causes relative cholinergic excess, which drives the dystonic movements. Injectable benztropine rapidly blocks muscarinic receptors in the striatum, restoring the balance and relieving the acute dystonia within minutes. Trihexyphenidyl is available only in oral form and is therefore used for chronic Parkinson's disease tremor management rather than acute situations. Subcutaneous rescue therapy for off episodes describes apomorphine. Intravenous reversal of levodopa-induced dyskinesias is not a role for anticholinergic agents — amantadine is the drug used for dyskinesias.

Correct Answer

C — Central muscarinic receptor blockade impairs memory and can precipitate delirium in elderly patients with reduced cognitive reserve

Rationale

The Beers Criteria listing of anticholinergic agents for Parkinson's disease is driven primarily by the central adverse effects of muscarinic blockade. Anticholinergic drugs cross the blood-brain barrier and block muscarinic receptors not only in the striatum — where the therapeutic effect occurs — but throughout the brain, impairing cholinergic neurotransmission that supports memory, attention, and cognitive processing. In elderly patients, particularly those with any preexisting cognitive impairment, this central muscarinic blockade can precipitate confusion, delirium, and accelerated cognitive decline. Younger patients with intact cognitive reserve can usually tolerate these central effects, which is why anticholinergic agents are reserved for younger patients with tremor-predominant disease. Peripheral effects such as urinary retention and constipation are real adverse effects of anticholinergics but are secondary concerns compared to the cognitive risks in elderly patients. Anticholinergic agents do not block dopamine receptors and do not reduce levodopa efficacy through pharmacological interaction.

Correct Answer

B — N-methyl-D-aspartate receptor antagonism reduces glutamatergic hyperexcitability (treats levodopa-induced dyskinesias) and enhanced dopamine release provides modest motor benefit (treats early Parkinson's disease symptoms)

Rationale

Amantadine operates through two pharmacological mechanisms with distinct clinical consequences. First, it blocks N-methyl-D-aspartate receptors — glutamate-gated ion channels in the striatum — reducing the glutamatergic hyperexcitability that drives levodopa-induced dyskinesias. This is amantadine's most clinically distinctive use: it is the only drug with established efficacy for reducing peak-dose dyskinesias without worsening motor control. Second, amantadine enhances dopamine release from surviving presynaptic dopaminergic terminals and may inhibit dopamine reuptake. This dopaminergic effect is modest but provides symptomatic benefit in early mild Parkinson's disease when enough neurons remain to respond. Monoamine oxidase B inhibition describes selegiline and rasagiline. Muscarinic receptor blockade describes benztropine and trihexyphenidyl. Amantadine's antiviral origin is historical context — it has no disease-modifying effect in Parkinson's disease.

Correct Answer

D — Anticholinergic-induced pupil dilation pushes the iris root against the trabecular meshwork, blocking aqueous outflow and precipitating acute angle-closure crisis

Rationale

Anticholinergic drugs block muscarinic receptors in the iris sphincter muscle, preventing the parasympathetically mediated pupil constriction. This causes pupil dilation — mydriasis. In a normal eye with a wide anterior chamber angle, mydriasis is well tolerated. In narrow-angle glaucoma, however, the angle between the iris and the cornea is already anatomically narrow. When the pupil dilates, the peripheral iris bunches up and presses against the trabecular meshwork, mechanically blocking aqueous humor outflow. Intraocular pressure rises acutely, producing the painful, vision-threatening emergency of acute angle-closure glaucoma. Anticholinergic drugs do not increase aqueous humor production and do not stimulate sympathetic receptors. Pupil constriction is the opposite of what anticholinergic drugs produce — miosis is produced by pilocarpine and other muscarinic agonists, which would actually open a narrow angle.

Correct Answer

A — Younger patients with tremor-predominant disease who cannot yet tolerate or do not yet require levodopa

Rationale

Anticholinergic agents correct the relative cholinergic excess that results from striatal dopamine depletion, making them most effective for tremor and, to a lesser extent, rigidity — features with a meaningful cholinergic component. They have little effect on bradykinesia, which is driven primarily by dopamine deficiency rather than cholinergic excess. Their usefulness is therefore concentrated in patients whose primary burden is tremor rather than bradykinesia. The combination of limited efficacy against bradykinesia and a high adverse effect burden — particularly central muscarinic blockade causing cognitive impairment and delirium — makes anticholinergic agents inappropriate for elderly patients, patients with significant functional impairment, and patients with any cognitive vulnerability. They are reserved for younger patients with tremor-predominant disease and adequate cognitive reserve. In patients with Parkinson's disease dementia, anticholinergic drugs are actively contraindicated because they worsen the cholinergic deficits that cholinesterase inhibitors are trying to compensate.

Correct Answer

C — Reduced renal clearance caused amantadine to accumulate to toxic levels; elderly patients with low cognitive reserve are especially vulnerable to its neuropsychiatric effects

Rationale

Two converging factors explain this patient's neuropsychiatric toxicity. First, amantadine is excreted unchanged by the kidneys, so his stage 3 chronic kidney disease reduces its clearance, causing plasma levels to rise above the therapeutic range at a dose that would be safe in a patient with normal renal function. Second, elderly patients — particularly those with Parkinson's disease, who often have preexisting cognitive vulnerability — are especially susceptible to the neuropsychiatric adverse effects of amantadine accumulation: confusion, hallucinations, and agitation. The combination of impaired renal clearance and reduced cognitive reserve creates a high-risk situation requiring dose reduction or drug discontinuation. Amantadine does not block dopamine receptors, produce neurotoxic metabolites, or inhibit monoamine oxidase B — its mechanisms are N-methyl-D-aspartate receptor antagonism and modest dopamine release enhancement.

Correct Answer

D — Amantadine provides only modest symptomatic benefit through its dopaminergic mechanism and is not adequate primary therapy for patients with significant functional impairment

Rationale

Amantadine's dopaminergic effect — enhancement of dopamine release from surviving presynaptic terminals — is modest compared to the robust and direct dopamine replacement provided by levodopa or the direct receptor stimulation of dopamine agonists. In early, mild Parkinson's disease with minimal functional impact, this modest effect can be sufficient for symptomatic management. As disease progresses and functional impairment develops, the degree of dopaminergic support required exceeds what amantadine can provide. At this point, levodopa is the appropriate transition. Amantadine does not develop receptor tolerance in a clinically meaningful way that explains its limitations. It does not cause motor fluctuations — those are a complication of levodopa therapy, and amantadine is actually used to treat them. Renal accumulation is a safety concern but is unrelated to the fundamental limitation of amantadine's motor efficacy in advanced disease.

Correct Answer

B — Haloperidol's dopamine D2 blockade created relative cholinergic excess in the striatum; injectable benztropine blocked muscarinic receptors, restoring the dopamine-acetylcholine balance

Rationale

Acute drug-induced dystonia results from dopamine D2 receptor blockade in the striatum. Under normal conditions, dopamine and acetylcholine activity in the striatum are balanced — dopamine counterbalances acetylcholine interneuron activity. When haloperidol blocks D2 receptors, dopamine signaling falls and acetylcholine activity becomes relatively dominant. This cholinergic excess drives the sustained involuntary muscle contractions that characterize acute dystonia. Benztropine reverses this imbalance by blocking muscarinic acetylcholine receptors in the striatum, reducing the cholinergic excess and restoring the dopamine-acetylcholine balance. Because benztropine is available in an injectable formulation — both intramuscular and intravenous — it can be administered for rapid relief in acute situations. The resolution within minutes reflects the rapid central anticholinergic effect of the injected drug. Haloperidol does not block N-methyl-D-aspartate receptors, does not accumulate neurotoxically in neurons, and its relevant pharmacological action is dopamine receptor blockade rather than serotonin receptor stimulation.

Correct Answer

A — Peripheral muscarinic blockade by anticholinergic drugs reduces detrusor muscle contractility, worsening urinary outflow obstruction in a bladder already compromised by prostatic enlargement

Rationale

The detrusor muscle of the bladder requires parasympathetic muscarinic stimulation to contract forcefully enough to overcome urethral resistance during voiding. In benign prostatic hyperplasia, the enlarged prostate already increases urethral resistance, placing greater demand on detrusor contractility to initiate and sustain urination. When an anticholinergic drug blocks muscarinic receptors in the detrusor, it reduces the force of bladder contraction further. In a patient whose detrusor is already working against elevated outflow resistance, this additional reduction in contractility can tip the balance into urinary retention — the inability to void despite a full bladder. This is why benign prostatic hyperplasia is a relative contraindication to anticholinergic agents. Anticholinergic drugs do not stimulate alpha-1 receptors — that is the mechanism of drugs such as midodrine. Central muscarinic blockade impairs cognition and memory but does not selectively block the cortical voiding reflex in the manner described. Anticholinergic drugs have no effect on prostatic smooth muscle growth.

Correct Answer

C — Peripheral muscarinic receptor blockade reducing parasympathetic tone in salivary glands, the detrusor muscle, and the gastrointestinal tract

Rationale

All three of this patient's complaints — dry mouth, urinary hesitancy, and constipation — result from peripheral muscarinic receptor blockade. Benztropine blocks muscarinic receptors throughout the body, not only in the striatum where its therapeutic effect occurs. In the salivary glands, parasympathetic muscarinic stimulation drives saliva production — blocking these receptors reduces secretion and causes dry mouth. In the bladder, muscarinic receptor stimulation of the detrusor muscle drives voiding contraction — blockade causes urinary retention and difficulty starting urination. In the gastrointestinal tract, parasympathetic tone drives peristalsis — muscarinic blockade slows motility and causes constipation. These effects are dose-dependent and occur with both benztropine and trihexyphenidyl. They are peripheral in origin — the same mechanisms would be produced by any peripherally acting anticholinergic drug. Central muscarinic blockade causes cognitive and neuropsychiatric effects rather than the peripheral visceral symptoms described here. N-methyl-D-aspartate antagonism describes amantadine's mechanism and does not produce these effects.